A prospective, randomized, double-blind, placebo-controlled multisite, parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab, a canine anti-nerve growth factor monoclonal antibody.
Veterinary anaesthesia and analgesia（2023）
摘要
These results corroborated those previously reported and provide further support of safety and effectiveness of bedinvetmab (0.5-1.0 mg kg) administered subcutaneously at monthly intervals to dogs for control of osteoarthritis-related pain.
更多查看译文
关键词
bedinvetmab,canine brief pain inventory,canine osteoarthritis,degenerative joint disease,monoclonal antibody,pain management
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要